Johnson & Johnson (NYSE:JNJ) said today that it controls nearly 78% of voting rights in its $30 billion acquisition of Swiss biotech firm Actelion (VTX:ATLN). Janssen, J&J’s Swiss subsidiary, declared the tender offer successful.
The company added that based on regulatory approval proceedings, the offer is expected to settle in the 2nd quarter of this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson’s tender offer for Actelion snares 78% stake appeared first on MassDevice.
from MassDevice http://ift.tt/2oGOSsE
Cap comentari:
Publica un comentari a l'entrada